After finishing at $2.04 in the prior trading day, 180 Life Sciences Corp (NASDAQ: ATNF) closed at $1.48, down -27.27%. On the day, 501399 shares were traded.
Ratios:
Our goal is to gain a better understanding of ATNF by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.72 and its Current Ratio is at 0.72.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Maxim Group on September 15, 2021, initiated with a Buy rating and assigned the stock a target price of $11.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’23 when Woody James N. bought 25,000 shares for $0.19 per share. The transaction valued at 4,700 led to the insider holds 66,888 shares of the business.
Feldmann Marc sold 25,000 shares of ATNF for $4,700 on Dec 15 ’23. The Director now owns 115,497 shares after completing the transaction at $0.19 per share. On Jun 01 ’23, another insider, STEINMAN LAWRENCE, who serves as the Director of the company, bought 18,000 shares for $1.23 each. As a result, the insider paid 22,068 and bolstered with 48,129 shares of the company.
Stock Price History:
Over the past 52 weeks, ATNF has reached a high of $27.93, while it has fallen to a 52-week low of $1.80.
Shares Statistics:
A total of 0.53M shares are outstanding, with a floating share count of 0.52M. Insiders hold about 3.20% of the company’s shares, while institutions hold 6.91% stake in the company.
Earnings Estimates
Its stock is currently analyzed by — different market analysts. On average, analysts expect EPS of $0 for the current quarter, with a high estimate of $0 and a low estimate of $0, while EPS last year was –$. The consensus estimate for the next quarter is $0, with high estimates of $0 and low estimates of $0.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is $0, with — analysts recommending between $0 and $0.
Revenue Estimates
Based on 1 analysts’ estimates, the company’s revenue will be $16.64M in the next fiscal year. The high estimate is $16.64M and the low estimate is $16.64M. The average revenue growth estimate for next year is up 0.20% from the average revenue estimate for this year.
